Fig. 1: Trial design and patient outcomes.
From: Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs
a Trial design showing dosing schedule, specimen collection, and IWG assessment timepoints for injected and oral phases. b Consort diagram summarising outcomes for all participants who were assessed for eligibility. c Swimmer plots showing participant response and outcome over time. Coloured squares indicate diagnosis for each patient (yellow—high risk (HR) MDS, purple—CMML, brown—low blast (LB) AML). Circles show response at IWG assessment or progression timepoints (blue—responder, orange—non-responder). The off-study reason for each patient is as indicated, the number in brackets indicates the number of treatment cycles completed, * denotes a single patient (P21) who was accelerated to the oral phase following 4 injection cycles.
